These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 39250331)
1. Efficacy and safety of two fixed doses of ibalizumab plus optimized background regimen in treatment-experienced HIV-positive individuals. DeJesus E; Towner WJ; Gathe JC; Cash RB; Anstett K J Acquir Immune Defic Syndr; 2024 Sep; ():. PubMed ID: 39250331 [TBL] [Abstract][Full Text] [Related]
2. Efficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study. Gathe JC; Hardwicke RL; Garcia F; Weinheimer S; Lewis ST; Cash RB J Acquir Immune Defic Syndr; 2021 Apr; 86(4):482-489. PubMed ID: 33427765 [TBL] [Abstract][Full Text] [Related]
3. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. Emu B; Fessel J; Schrader S; Kumar P; Richmond G; Win S; Weinheimer S; Marsolais C; Lewis S N Engl J Med; 2018 Aug; 379(7):645-654. PubMed ID: 30110589 [TBL] [Abstract][Full Text] [Related]
4. Ibalizumab for the treatment of multidrug-resistant HIV-1 infection. Rizza SA; Bhatia R; Zeuli J; Temesgen Z Drugs Today (Barc); 2019 Jan; 55(1):25-34. PubMed ID: 30740610 [TBL] [Abstract][Full Text] [Related]
5. Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection. Beccari MV; Mogle BT; Sidman EF; Mastro KA; Asiago-Reddy E; Kufel WD Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30885900 [TBL] [Abstract][Full Text] [Related]
6. Indirect Treatment Comparisons of Lenacapavir Plus Optimized Background Regimen Versus Other Treatments for Multidrug-Resistant Human Immunodeficiency Virus. Chatzidaki I; Curteis T; Luedke H; Mezzio DJ; Rhee MS; McArthur E; Eddowes LA Value Health; 2023 Jun; 26(6):810-822. PubMed ID: 36566886 [TBL] [Abstract][Full Text] [Related]
7. Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection. Blair HA Drugs; 2020 Feb; 80(2):189-196. PubMed ID: 31970712 [TBL] [Abstract][Full Text] [Related]
8. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Jacobson JM; Kuritzkes DR; Godofsky E; DeJesus E; Larson JA; Weinheimer SP; Lewis ST Antimicrob Agents Chemother; 2009 Feb; 53(2):450-7. PubMed ID: 19015347 [TBL] [Abstract][Full Text] [Related]
9. US cost-utility model of lenacapavir plus optimized background regimen (OBR) vs fostemsavir plus OBR and ibalizumab plus OBR for people with HIV with multidrug resistance. Vardanega V; New E; Mezzio D; Eddowes LA J Manag Care Spec Pharm; 2024 Sep; 30(9):1001-1012. PubMed ID: 39213144 [TBL] [Abstract][Full Text] [Related]
10. Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States. Millham LRI; Scott JA; Sax PE; Shebl FM; Reddy KP; Losina E; Walensky RP; Freedberg KA J Acquir Immune Defic Syndr; 2020 Feb; 83(2):148-156. PubMed ID: 31929403 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lataillade M; Lalezari JP; Kozal M; Aberg JA; Pialoux G; Cahn P; Thompson M; Molina JM; Moreno S; Grinsztejn B; Diaz RS; Castagna A; Kumar PN; Latiff GH; De Jesus E; Wang M; Chabria S; Gartland M; Pierce A; Ackerman P; Llamoso C Lancet HIV; 2020 Nov; 7(11):e740-e751. PubMed ID: 33128903 [TBL] [Abstract][Full Text] [Related]
12. Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C. Zeuzem S; Yoshida EM; Benhamou Y; Pianko S; Bain VG; Shouval D; Flisiak R; Rehak V; Grigorescu M; Kaita K; Cronin PW; Pulkstenis E; Subramanian GM; McHutchison JG Hepatology; 2008 Aug; 48(2):407-17. PubMed ID: 18666223 [TBL] [Abstract][Full Text] [Related]
13. Darunavir: a review of its use in the management of HIV infection in adults. McKeage K; Perry CM; Keam SJ Drugs; 2009; 69(4):477-503. PubMed ID: 19323590 [TBL] [Abstract][Full Text] [Related]
15. Ibalizumab and Fostemsavir in the Management of Heavily Pre-Treated HIV-infected Patients. Riccardi N; Berruti M; Del Puente F; Taramasso L; Di Biagio A Recent Pat Antiinfect Drug Discov; 2018; 13(3):190-197. PubMed ID: 30378502 [TBL] [Abstract][Full Text] [Related]
16. Antibody-based strategies in HIV therapy. Kufel WD Int J Antimicrob Agents; 2020 Dec; 56(6):106186. PubMed ID: 33045349 [TBL] [Abstract][Full Text] [Related]
17. Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab. Toma J; Weinheimer SP; Stawiski E; Whitcomb JM; Lewis ST; Petropoulos CJ; Huang W J Virol; 2011 Apr; 85(8):3872-80. PubMed ID: 21289125 [TBL] [Abstract][Full Text] [Related]
18. Ibalizumab: The First Monoclonal Antibody for the Treatment of HIV-1 Infection. Chahine EB; Durham SH Ann Pharmacother; 2021 Feb; 55(2):230-239. PubMed ID: 32659101 [TBL] [Abstract][Full Text] [Related]
19. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235 [TBL] [Abstract][Full Text] [Related]
20. Comparative Efficacy and Safety of Fostemsavir in Heavily Treatment-Experienced People With HIV-1. Anderson SJ; van Doornewaard A; Turner M; Jacob I; Clark A; Browning D; Schroeder M Clin Ther; 2022 Jun; 44(6):886-900. PubMed ID: 35610081 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]